The FY2025 (Dec) proxy of Oruka Therapeutics names 18 peer companies for pay. Among Oruka Therapeutics and these peers, CEO pay was the lowest of 5 and total shareholder return was 4th highest of 5.
5th highest of 5in Oruka Therapeutics and its pay peers, FY2025 (Dec) by CEO pay:
$3.4M$8.5M
4th highest of 5in Oruka Therapeutics and its pay peers, FY2025 (Dec) by total shareholder return:
$17$268
Pay peer group, FY2025 (Dec) proxy
| Kymera Therapeutics | ||
| Structure Therapeutics | ||
| Spyre Therapeutics | ||
| Celldex Therapeutics | ||
| Apogee Therapeutics | Not disclosed | Not disclosed |
| Astria Therapeutics | Not disclosed | Not disclosed |
| CARGO Therapeutics | Not disclosed | Not disclosed |
| Cabaletta Bio | Not disclosed | Not disclosed |
| Contineum Therapeutics | Not disclosed | Not disclosed |
| Entrada Therapeutics | Not disclosed | Not disclosed |
| Janux Therapeutics | Not disclosed | Not disclosed |
| Kyverna Therapeutics | Not disclosed | Not disclosed |
| Lexeo Therapeutics | Not disclosed | Not disclosed |
| Longboard Pharmaceuticals | Not disclosed | Not disclosed |
| Lyell Immunopharma | Not disclosed | Not disclosed |
| Pliant Therapeutics | Not disclosed | Not disclosed |
| Prime Medicine | Not disclosed | Not disclosed |
| Third Harmonic Bio | Not disclosed | Not disclosed |
18 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.